Pyridoxamine improves metabolic and microcirculatory complications associated with nonalcoholic fatty liver disease.

Evelyn Nunes Goulart da Silva PereiraRaquel Rangel SilvaresEdgar Eduardo Ilaquita FloresKarine Lino RodriguesAnissa Daliry

Published in: Microcirculation (New York, N.Y. : 1994) (2020)

Pyridoxamine modulates oxidative stress, advanced glycation end products, TNF-α transcripts levels, and metabolic disturbances, being a potential treatment for nonalcoholic fatty liver disease-associated microcirculatory and metabolic complications.

Keyphrases

oxidative stress
risk factors
dna damage
liver fibrosis
diabetic rats
replacement therapy
smoking cessation